Recent evidence in follicular lymphoma further demonstrates that activating mutations in STAT6 sensitize tumor cells to IL-4, driving downstream mTOR pathway activation and compensating for CREBBP deficiency. This evidence concerns the gene IL4 and follicular lymphoma.